News

Hear Anu Lala, MD, discuss how she turned a moment of childhood fascination into a lifelong career of caring for patients.

Heather O'Connell, PA-C, makes the case that missing rhinitis, nasal polyps, or NSAID sensitivity is costing patients exacerbations and hospitalizations.

Katherine Tuttle, MD, discusses shifting the goals of chronic kidney disease management from slowing progression to preserving kidney function.

Matthew Zirwas, MD, on using dupilumab and lebrikizumab to guide patch testing decisions and the 2 most missed allergens in eczematous disease.

First placebo-controlled phase 3 METRE-PL data show prevalent metabolic burden in familial partial lipodystrophy (FPLD) despite standard therapy.

In the latest Skin of Color Savvy episode, Umayr Shaikh, MPH, shares how his work is shaping his medical career.

John Sonnenberg, PhD, reflects on Emerge Phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

This episode covers the recent trial of the Signos weight loss platform, indicating weight loss that could challenge GLP-1 receptor agonists.

Zobair Younossi, MD, explains how lifestyle, drugs, and EXCEL data show steatosis and fatigue improvements in MASLD.

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

In the final segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the fourth segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the third segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the second segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

In the first segment of this 5-part HCPLive Special Report, experts recap the Obesity Medicine Association Annual Conference 2026.

HCPLive previews Maui Derm NP+PA Summer 2026, covering sessions on atopic dermatitis, acne, psoriasis, pigmentation disorders, and more.

This segment of Lio's RAD Conference interview in Nashville highlights the growing number of therapeutics and an increasingly personalized approach.

The CNP at Cleveland Clinic discusses how early recognition, cross-specialty collaboration, and extended patient engagement make APPs essential in the complex, long-term care of interstitial lung disease.

Panelists reached broad consensus that upfront dual oral combination therapy with an ERA and PDE5 inhibitor remains the foundational standard.

EPL reduced hepatic steatosis vs placebo in EXCEL MASLD trial, meeting primary endpoint at 6 months by CAP FibroScan assessment.

Peter Lio, MD, spoke at the RAD 2026 conference about the upcoming AAD pediatric guidelines for atopic dermatitis.

Michal Meron, MD, discusses her recent study indicating the potential role of the TYG index in predicting liver disease among patients without diabetes with confirmed MASLD.

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

FDA cited manufacturing and labeling issues in its CRL for cytisinicline, with no clinical efficacy or safety deficiencies reported.

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.